Effects of a lipase inhibitor (Orlistat) on cholecystokinin and appetite in response to a high-fat meal

What Was Tested

This randomized controlled trial paper looks at Cholecystokinin (CCK).

To examine the short-term effects of a lipase inhibitor (Orlistat) on physiological and behavioural measures of appetite in response to a high-fat meal.

Who Took Part

According to the abstract, 19 subjects were involved.

PubMed indexes the participants as adults, men only.

A total of 19 healthy nonobese male subjects.

How the Study Was Run

The design is described as randomized, single-blind, placebo-controlled and crossover.

The subjects were allocated by chance, so the Cholecystokinin (CCK) group and the comparison group should start out alike.

In this single-blind Cholecystokinin (CCK) study one party knew the assignments and the other did not.

A placebo (an inactive look-alike) gave the Cholecystokinin (CCK) group a baseline to be compared against.

Each person switched between Cholecystokinin (CCK) and the comparison at some point, usually with a gap in between.

Randomised, single blind, placebo-controlled, crossover trial.

Appetite, as assessed by a standard line scale, and plasma cholecystokinin (CCK) concentrations were measured prior to and every hour after the test meal for 4 h.

What Was Measured

The subject headings attached to it are Anti-Obesity Agents, Appetite, Cholecystokinin, Dietary Fats, Eating, Enzyme Inhibitors and Hunger.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Cholecystokinin (CCK) in 19 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2003 (International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity), a journal based in England.

More context: the Cholecystokinin (CCK) compound page, all human trials.